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Extreme morning chronotypes are often familial and not 
exceedingly rare: the estimated prevalence of advanced sleep 
phase, familial advanced sleep phase, and advanced sleep–
wake phase disorder in a sleep clinic population
Brian John Curtis1, Liza H. Ashbrook2, , Terry Young3, Laurel A. Finn3,  
Ying-Hui Fu2, Louis J. Ptáček2,* and Christopher R. Jones4
1Department of Psychology, University of Utah, Salt Lake City, UT, 2Department of Neurology, University of California San 
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Medicine and Public Health, Madison, WI and 4Department of Neurology, University of Utah, Salt Lake City, UT
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Abstract
Study Objectives: Report the first prevalence estimates of advanced sleep phase (ASP), familial advanced sleep phase (FASP), and advanced sleep–wake phase disorder 
(ASWPD). This can guide clinicians on the utility of screening for extreme chronotypes both for clinical decision-making and to flag prospective participants in the study of 
the genetics and biology of FASP.
Methods: Data on morning or evening sleep schedule preference (chronotype) were collected from 2422 new patients presenting to a North American sleep center over 
9.8 years. FASP was determined using a severity criterion that has previously identified dominant circadian mutations in humans. All patients were personally seen and 
evaluated by one of the authors (C.R.J.).
Results: Our results demonstrate an ASP prevalence of 0.33%, an FASP prevalence of 0.21%, and an ASWPD prevalence of at least 0.04%. Most cases of young-onset 
ASP were familial.
Conclusions: Among patients presenting to a sleep clinic, conservatively 1 out of every 300 patients will have ASP, 1 out of every 475 will have FASP, and 1 out of 
every 2500 will have ASWPD. This supports obtaining a routine circadian history and, for those with extreme chronotypes, obtaining a family history of circadian 
preference. This can optimize treatment for evening sleepiness and early morning awakening and lead to additional circadian gene discovery. We hope these findings 
will lead to improved treatment options for a wide range of sleep and medical disorders in the future.
Key words: advanced sleep phase; advanced sleep-wake phase disorder; familial advanced sleep phase; circadian; prevalence
Statement of Significance
There are currently no prevalence estimates of advanced sleep phase (ASP), familial advanced sleep phase (FASP), and advanced sleep–wake phase disorder 
(ASWPD) to assist clinicians in deciding whether to screen for this sleep pattern in routine clinic visits and to assist researchers in identifying FASP individuals and 
their families. Our sleep clinic, which routinely screens for circadian phenotype, provides a good forum from which to determine prevalence of FASP. Our results 
demonstrate an ASP prevalence of 0.33%, an FASP prevalence of 0.21%, and an ASWPD prevalence of at least 0.04%. Most cases of young-onset ASP were familial. 
This suggests that approximately 1 out of every 475 new patients presenting to a sleep clinic will also have FASP, making every sleep center an ideal location to 
further our understanding of circadian clock gene influences on human health and disease.
SLEEPJ, 2019, 1–9
doi: 10.1093/sleep/zsz148
Advance Access Publication Date: 6 August 2019
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D
ow
nloaded from
 https://academ
ic.oup.com
/sleep/advance-article-abstract/doi/10.1093/sleep/zsz148/5542813 by U
niversity of C
alifornia, San Francisco user on 19 August 2019
2 | SLEEPJ, 2019, Vol. XX, No. XX
Introduction
Advanced sleep phase (ASP) is characterized by a stable and un-
usually phase-advanced circadian sleep–wake rhythm relative 
to local solar time. We refer to familial advanced sleep phase 
(FASP) when ASP is demonstrated in multiple biologically re-
lated family members [1]. Advanced sleep–wake phase dis-
order (ASWPD) is defined as a marked phase advance of the 
sleep–wake cycle accompanied by a sleep related complaint [2]. 
FASP is a subtype of ASP and overlaps with ASWPD (Figure 1). 
Identifying these individuals in a clinical setting appears chal-
lenging as they are presumed to be very rare. As the third edi-
tion of the International Classification of Sleep Disorders (ICSD-3) 
observes, “The existing literature suggests that clinicians are 
unlikely to encounter patients with stringently defined ASWPD.” 
[2] The rarity of encountering patients with stringently defined 
ASWPD is likely a result of the diagnostic requirement for a 
chronic or recurrent complaint related to the patient’s advanced 
sleep–wake schedule [2]. Indeed, in patients with young-onset 
ASP, their early morning awakening may not be perceived as a 
school or work problem, but rather as an advantage. This may 
explain why ASP was thought to be exceedingly rare in the gen-
eral population [3]. Many such individuals do not seek medical 
attention for their ASP. Prior to 1999, the authors are aware of 
only two convincing case reports of severe, young-onset ASWPD 
[4, 5]. Young-onset ASWPD was initially thought to be sporadic, 
but one of these case reports alluded to a family history [4]. Two 
other case reports are difficult to interpret due to conventional 
morning wake time and difficulty maintaining sleep in one re-
port [6] and late age of onset in another [7].
Another potential obstacle to the clinical identification of 
patients with ASP, FASP, and ASWPD is a lack of recommended 
cutoff scores on widely used circadian questionnaires to reliably 
suggest unusual circadian phase advance. Two questionnaires 
commonly used for this purpose are the Munich Chronotype 
Questionnaire (MCTQ) [8] and the Horne–Ostberg Morningness/
Eveningness Questionnaire (MEQ) [9]. Data from the growing 
MCTQ database of Roenneberg et al. [8] suggest that individual 
sleep schedule on free days, a marker of chronotype, is approxi-
mately normally distributed and varies with latitude, geograph-
ical region, and urban or rural lifestyle [10]. Using midpoint of 
sleep on work-free days (MSF) calculations, chronotype has 
been shown to delay by 4 minutes for each degree of longitude 
one moves from east to west, even within the same time zone 
[10]. The average MSF corrected for extra catch-up sleep on the 
weekends (MSFsc) also has a latitudinal dependence. In the 
northerly latitudes of central Europe, MSFsc is centered on 04:00, 
whereas MSF distribution in India centers on 03:00. Therefore, 
“intermediate” chronotypes in central Europe would be “late 
types” in India [11]. Chronotype also has a strong age depend-
ence, with rapidly increasing phase delay through adolescence 
that peaks sharply at age 20  years and is followed by a grad-
ually slowing but persistent trend back toward typical childhood 
chronotype by the eighth decade [12]. Therefore, ideal criteria 
for ASP might incorporate age, latitude, and longitude. However, 
to allow for routine clinical use, our experience identifying and 
phenotyping FASP kindreds in North America suggests that in-
dividuals and families with an MSF less than or equal to 01:30, 
MEQ scores at least 71, and onset of these sleep schedules 
occurring prior to the age of 30 years likely have a familial form 
of ASP [1, 13–19].
In 1999, three families containing a total of 29 strikingly 
phase-advanced individuals were reported by one of the authors 
(C.R.J.) under the descriptive term “Familial Advanced Sleep 
Phase Syndrome (FASPS).” [1] We have modified the term to 
“Familial Advanced Sleep Phase (FASP)” as “syndrome” may con-
note a disorder to some whereas many FASP individuals have 
no complaint about their sleep schedule. One of these families 
was used to genetically map and clone the first reported human 
circadian clock gene mutation in the PER2 gene [1, 13]. The ASP 
probands in this study were discovered by C.R.J.  because they 
came to clinical attention with complaints suggestive of ob-
structive sleep apnea (OSA). Owing to the absence of circadian 
complaints, most ASP probands would not meet ICSD-3 diag-
nostic criteria for ASWPD [20]. For this reason, we refer to in-
dividuals and families with the onset of extreme sleep phase 
advance by age 30 years as ASP and FASP, respectively.
The ASP participants reported here were living urban life-
styles within the North American state of Utah, comparable with 
the MCTQ central European database. The initial MCTQ database 
(N = 500) suggested that no more than 2% of the general popula-
tion in Germany and Switzerland were self-described “extreme 
early types,” with only 0.8% having MSF less than or equal to 
02:00 [8]. Expansion of the MCTQ database (N ≈ 25 000)  found 
estimates of approximately 2% of the general population with 
MSF less than or equal to 02:00 and approximately 0.67% with 
MSF less than or equal to 01:30 [12]. A more recent expansion 
of the MCTQ database of central European responders (N = 92 
567)  found a mean MSF (not corrected for workweek sleep 
Figure 1. Venn diagram of relationship between ASP, FASP, ASWPD, and ASP of aging. The relative size of the circles does not reflect the relative prevalence of ASP versus 
ASP of aging, as the prevalence of ASP of aging is not known.
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deprivation) of 04:58 (±1.56), 2.89% with MSF less than or equal 
to 02:00, and 0.97% with MSF less than or equal to 01:30 (per-
sonal communication, T.  Roenneberg in 2012). Correcting for 
latitude predicts a mean Utah MSF of 04:37. If our clinic popula-
tion is representative of the local population, this would repre-
sent the mean MSF for those presenting to the clinic.
Comparing the MCTQ with another widely used tool to as-
sess chronotype, the MEQ [9], revealed reasonable correlations 
between MEQ and MSF scores (r  =  −0.73) in a predominantly 
young adult Dutch population (N = 2481) [21]. Pooling MEQ data 
from 741 young adults, 484 adults, and 40 elderly participants 
in London and the United States yielded a weighted prevalence 
estimate of extreme morningness (i.e. MEQ scores ≥71) of ap-
proximately 0.51% [22–25]. Taken together, the MCTQ and MEQ 
databases would predict a prevalence of individuals with ex-
treme morning chronotypes resembling ASP (i.e. MSF ≤ 01:30 
and MEQ ≥ 71) to range between 0.50% and 1.00% in the North 
American general population. Whether a similar prevalence 
range accurately reflects the prevalence of individuals with 
young-onset ASP and FASP is currently unknown.
To address this question, we report here the first estimated 
prevalence of young-onset ASP, FASP, and ASWPD obtained 
from a sleep clinic population. Data on self-report and ob-
jective methods used to characterize chronotype and circadian 
rhythms in young-onset ASP, FASP, and ASWPD participants are 
provided. Next, differences in self-reported markers of circadian 
rhythms, excessive daytime sleepiness (EDS), and depressive 
affect in young-onset ASP participants and their conventional 
chronotype family members were examined. Finally, we explore 
whether apnea–hypopnea index (AHI) predicts MEQ-determined 
chronotype to gauge whether using a population presenting 
with symptoms of OSA has potential for generalizability of the 
results.
Methods
Research approval for this study was obtained from the 
University of Utah Institutional Review Board.
Participants
As in many general sleep disorder clinics, most participants pre-
sented for signs and symptoms concerning for OSA. This is not 
surprising, given the high prevalence of OSA in men and women 
and the availability of clinical treatment options [2]. Name, hos-
pital medical record number, date of first visit, new versus re-
turn physician evaluation code, and diagnosis code numbers 
for all patients seen by C.R.J. from January 1994 to October 2003 
were imported from our hospital’s scheduling and billing com-
puter record system into an Excel spreadsheet. The spreadsheet 
was then edited to delete patient encounters other than the 
initial patient visit. Computer data entry from January 1994 to 
August 1995 did not use sufficiently specific sleep disorder diag-
nosis codes or discriminate nighttime sleep laboratory proced-
ures performed by technologists from daytime clinic visits with 
the physician. However, of the 637 encounters from this period, 
571 complete paper charts were available for review and the ap-
propriate diagnosis and procedure codes were manually entered 
into the edited spreadsheet. The total number of patients seen 
was 2422, of whom 1748 (72.2%) had suspected or proven OSA.
Screening for ASP
Careful screening for ASP began following identification of the first 
FASP proband seen by C.R.J. in November of 1992. This 72-year-old 
female was first described in 1999 [1]. Habitual workday and free day 
sleep schedules were routinely discussed with patients during their 
initial clinic visit, given the relevance of sleep timing to all sleep dis-
orders. Patients describing MSF less than or equal to 01:30 with onset 
of this sleep schedule prior to age 30 years were informed of our re-
search following their clinic visit. Willing participants signed a con-
sent form approved by the University of Utah Institutional Review 
Board. Initial contact and enrollment of patient’s family members 
was accomplished by telephone, email, or US Postal Service.
Expanded phenotyping of patients screening 
positive for ASP and their family members
Enrolled participants were asked to complete six question-
naires: (1) Participant Information Form detailing demographic 
information and family medical history; (2) Epworth Sleepiness 
Scale (ESS) [26]; (3) A  “General Sleep Questionnaire” (GSQ) de-
signed to assess habitual workday and free day sleep schedules, 
sleep disorders, medical history, and psychosocial influences 
on sleep (Supplementary Figure 1); (4) A  visual analog “Wake 
and Sleep Questionnaire” developed to assess latencies from 
lights out to initial sleep onset and from final sleep offset to 
getting out of bed (Supplementary Figure 2); (5) Morningness/
Eveningness Questionnaire [9]; and (6) Beck Depression Inventory 
II (BDI-II) [27]. Participants also completed a 45–60 minute-
structured telephone interview conducted by C.R.J. or a trained 
research coordinator. Interview questions included habitual 
workday and free day sleep schedules, alarm use, daytime nap-
ping, daily rhythms of mood and alertness, effects of seasonal 
and time zone changes on sleep, confounding influences on 
sleep (e.g. caffeine, alcohol, medications), age-related changes 
in sleep schedule, and age-related history of chronotype from 
childhood to the present (Supplementary Figure 3). This detailed 
screening included evaluation for alternative causes of early 
morning awakening, such as depression, daytime obligations, 
insomnia, and OSA.
When possible, questionnaires and structured interview 
results were compared with in-laboratory polysomnography 
(PSG), home sleep-stage recordings, and 10-day ambulatory 
wrist actigraphy with coincident sleep logs, and one evening of 
salivary dim light melatonin onset (DLMO). The phase angle be-
tween melatonin onset and the sleep–wake cycle has been cor-
related with endogenous circadian period [28] and the DLMO 
itself estimates the magnitude of circadian rhythm advance 
or delay. PSG was recorded and scored according to standard 
procedures [29, 30]. Home sleep-stage recordings were per-
formed using the Zeo automated wireless system (Zeo, Inc., 
Newton, MA) that has shown reliability with in-laboratory PSG 
[31] and outpatient actigraphy and sleep logs [32]. Actigraphy 
was performed using the MicroMini-Motionlogger (Ambulatory 
Monitoring, Inc., Ardsley, NY) and Actiwatch-L (Respironics, 
Murrysville, PA) actigraphs. Actigraphy data were downloaded 
using Action-W 2.4.17 and Actiware-Sleep 3.4 software and 
scored automatically using the Cole-Kripke sleep algorithm. 
Saliva samples to determine DLMO were collected every 30 min-
utes for 5–6 hours before habitual bedtime on nonworkdays by 
participants in their homes using “Salivette” saliva collection 
tubes (Sarstedt, Inc., Newton, NC). SolidPhase, Inc. (Portland, ME) 
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analyzed saliva melatonin content using the BUHLMANN Direct 
Saliva Melatonin Radio Immunoassay (ALPCO Diagnostics, 
Salem, NH). Participants were instructed to remain in less than 
or equal to 30 lux of dim lighting throughout their saliva col-
lection protocol. Lux values were obtained using the Sinometer 
LX1010B Mini Digital Lux Meter (ShenZhen, China) and recorded 
on a saliva collection log at the time of each saliva sample.
ASP criteria included the following: (1) the ability to fall 
asleep before 20:30 and to wake before 05:30 throughout the 
year in the absence of professional or psychosocial demands or 
environmental influences (e.g. early morning work start time, 
self-imposed morning bright light); (2) the presence of only one 
major sleep period each day; (3) onset of this stable sleep–wake 
schedule before the age of 30 years; (4) the sleep pattern is not 
maintained by morning stimulants or evening sedative use; (5) 
the sleep pattern did not develop within 3 months of a traumatic 
brain injury; and (6) the sleep pattern is not due to another med-
ical, neurological, or mental disorder (e.g. chronic insomnia dis-
order, major depressive disorder).
AHI predicting MEQ-determined chronotype
To gauge whether an OSA population is skewed toward 
morningness or eveningness, we assessed whether AHI selects 
for MEQ using the Wisconsin Sleep Cohort. Repeated measures 
linear regression analysis (PROC MIXED, SAS) was performed on 
MEQ and the log of the AHI scores from 3188 studies on 1324 
participants from the Wisconsin Sleep Cohort. The Wisconsin 
Sleep Cohort’s methods for collection and interpretation of PSG 
recordings and AHI scores have been described [33].
Results
Estimated North American prevalence of early-onset 
ASP and FASP
Eight patients with ASP (three females) were identified and en-
rolled from January 1994 to October 2003 (9.8 consecutive years). 
Seven ASP subjects presented with EDS as their primary com-
plaint. The eighth ASP subject presented with a previous diag-
nosis of OSA, complaining of nasal continuous positive airway 
pressure mask discomfort. Diagnostic PSG demonstrated OSA in 
all five male ASP subjects. The first female ASP proband had sus-
pected upper airway resistance syndrome and declined PSG and 
multiple sleep latency testing (MSLT), anticipating a change in 
her condition after completion of her pregnancy. Subsequently, 
she had upper airway surgery with self-reported resolution of 
her hypersomnia. The second female ASP proband presented 
with worsening EDS secondary to a previous diagnosis of nar-
colepsy without cataplexy. Diagnostic PSG demonstrated ob-
structive hypopneas of mild degree (AHI = 11) plus respiratory 
effort–related arousals of approximately five per hour in supine 
and lateral positions. The third female proband was diagnosed 
with insufficient sleep associated with ASP syndrome and pos-
sible idiopathic hypersomnia without long sleep time following 
PSG and MSLT recordings.
No ASP probands presented with chief complaint of their 
advanced schedule, and it was thought to contribute to the ul-
timate diagnosis in one of eight patients. Two probands had ASP 
onset before the age of 12 years and the remaining six probands 
had ASP onset before the age of 22 years. All eight ASP probands 
reported at least one first-degree relative with a similarly ad-
vanced sleep–wake schedule, suggesting FASP. At least one rela-
tive with ASP from each proband was willing to be interviewed 
for research purposes. Family member enrollment and circa-
dian phenotyping revealed 15 ASP participants in five families, 
confirming FASP in five kindreds consistent with an autosomal 
dominant mode of transmission (Figure 2). Two ASP relatives 
had age of onset by age 40 years, with the remaining ASP rela-
tives having onset prior to the age of 22 years.
Of the 2422 patients that were seen from January 1994 to 
October 2003, eight ASP probands and five FASP kindreds were 
identified who met our ASP criteria. One ASP proband had a sleep 
complaint related to her advanced sleep schedule. Therefore, 
the estimated prevalence of early-onset ASP, FASP, and ASWPD 
among patients pursuing evaluation at a North American aca-
demic medical center is 0.33% (8/2422), 0.21% (5/2422), and 0.04% 
(1/2422), respectively (Figure 3). We consider these estimates to 
be conservative, as four subjects describing FASP declined re-
search participation and were not included in the above results. 
If these four individuals do, in fact, have ASP, the ASP prevalence 
estimate is 0.50% (12/2422). Assuming the four to have FASP, 
an upper estimate of FASP from the dataset would be 0.37% 
(9/2422). Further, more mild sleep patterns that did not meet our 
strict criteria were seen in family members of the three ASP in-
dividuals who were not categorized as FASP. Four additional in-
dividuals and eight of their relatives were also initially enrolled 
in our study but ultimately were not included in this data due to 
not meeting the strict criteria.
We also considered the prevalence estimate for ASP and 
FASP among the population pursuing evaluation for OSA whose 
ASP was not thought to directly contribute to the diagnosis. Of 
the 1748 patients with suspected or proven OSA that were seen 
from January 1994 to October 2003, seven patients met criteria 
for ASP and four for FASP. Therefore, the estimated prevalence of 
early-onset ASP and FASP among patients pursuing evaluation 
at a North American academic medical center for symptoms of 
OSA is 0.40% (7/1748) and 0.23% (4/1748), respectively.
Chronotype and circadian rhythm markers of 
young-onset ASP and FASP participants
MEQ scores, MSF times, and saliva DLMO for the ASP probands 
and their ASP relatives are included in Table 1.
Fourteen non-advanced and non-delayed (i.e. “conventional”) 
chronotype family members were also identified and character-
ized in our ASP and FASP kindreds. Comparison between self-
reported markers of circadian rhythms, EDS, and depressive 
affect in ASP participants and their conventional chronotype 
family members are included in Table 2. Comparison of MSF and 
MEQ in the ASP cohort versus the conventional sleeping family 
members is demonstrated in supplementary Figure 4.
AHI severity does not predict MEQ-determined 
chronotype
The majority of the ASP and FASP probands in this investigation 
pursued evaluation at an academic medical center for symptoms 
of potential OSA. To assess if OSA selects for chronotype, data 
were obtained MEQ and AHI scores from 3188 studies on 1324 
D
ow
nloaded from
 https://academ
ic.oup.com
/sleep/advance-article-abstract/doi/10.1093/sleep/zsz148/5542813 by U
niversity of C
alifornia, San Francisco user on 19 August 2019
Curtis et al. | 5
participants from the Wisconsin Sleep Cohort [33]. Repeated 
measures linear regression analysis revealed no significant pre-
dictive relationship between MEQ-determined early morning or 
late night sleep schedule preference and AHI severity (Figure 4).
Discussion
In this study, we provide the first prevalence estimates of ASP, 
FASP, and ASWPD based on a sleep clinic population. All pa-
tients were personally seen and evaluated by one of our authors 
(C.R.J.). Of the eight young-onset ASP probands, five FASP fam-
ilies were identified who met our strict ASP criteria. Estimates 
show an ASP prevalence of 0.33% (8/2422), FASP prevalence of 
0.21% (5/2422), and ASWPD prevalence of 0.04% (1/2422) (Figure 
3). Of the 2422 total patients, 1748 presented for OSA. Therefore, 
the estimated prevalence in an OSA population is 0.40% (7/1748) 
for ASP and 0.23% (4/1748) for FASP. As the eighth proband did 
not have OSA and instead had a complaint related to FASP, she 
meets criteria for ASWPD and is not included in the estimate 
from an OSA population.
Data characterizing chronotype and circadian rhythms using 
subjective and objective methods for the eight young-onset ASP 
probands and their ASP family members in this study are given 
in Table 1. Clock times are reported in participants’ local time 
zone and not solar time. MCTQ data from 21 600 German par-
ticipants strongly suggests that the human circadian clock is 
predominantly entrained by solar time rather than local legal 
(“social”) time [10]. Therefore, we consider our phenotyping 
to be conservative, as four ASP probands and one ASP relative 
performed recordings during Daylight Saving Time, effectively 
delaying these clock times by 1 hour in reference to solar time. 
Three ASP probands (32966, 101344, and 51146)  reported rou-
tinely delaying their evening sleep onset to avoid early morning 
awakening, making their advanced MSF times all the more im-
pressive. Proband 101263 denied delaying evening sleep onset, 
and we were unable to collect this information from probands 
Figure 2. FASP pedigrees. Circles, females; squares, males; diagonal line through symbols, deceased; numbers underneath symbols, DNA identifier; arrows, probands.
Figure 3. Flow chart of patient enrollment and prevalence estimates.
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25823, 28414, 100381, and 101311. Salivary DLMOs collected on 
170 North American adult participants (85 females, average 
MEQ = 52.11 ± 9.10) revealed a mean DLMO of 20:50 (±1:12) [34]. 
Using the same method of DLMO calculation, ASP proband 
101311 is within the earliest 0.21% of this normative database. 
Similarly, ASP proband 28414 and ASP family member 101382 are 
within the earliest 0.50% and 20.5% of this normative database, 
respectively. As 101382 performed her DLMO during Daylight 
Saving Time, she would be predicted to be within the earliest 
4.7% of this normative database using solar (i.e. nonsocial) time. 
Owing to financial constraints, sleep logs, actigraphy, Zeo, DLMO, 
and PSG data were collected on fewer conventional chronotypes 
than ASP participants, limiting statistical comparisons on these 
measures.
Significant differences in MSF clock times and MEQ scores 
between ASP participants and their conventional chronotype 
family members were expected given our ASP classification 
criteria (Table 2, Supplementary Figure 4). The tendency to-
ward rigid sleep schedules on workdays (midpoint of sleep on 
workdays) and nonworkdays (MSF) in “extreme early types” has 
been reported in a large North American FASP kindred [1] and a 
European study using the MCTQ [8]. Our data confirm this ten-
dency. Young-onset ASP participants sleep an average of 5–10 
minutes later on weekends compared to an average of 30–38 
Table 1.  Chronotype and circadian rhythm markers of young-onset ASP and FASP participants
Kindred; ID MEQ GSQ MSF Intrvw MSF Earliest MSF SL MSF Zeo MSF ACT MSF PSG MSF DLMO
5094; 32966 80 1:03 0:32 23:53 — — 0:53† 1:19 —
5094; 35215 82 — 1:04 0:13 — — — — —
5094; 35213 68 1:38 1:38 — — — — — —
50212; 101344 78 1:05 2:05 0:45 — — — 1:09† —
50212; 101326 72 2:10 1:11 23:23 1:45† 1:58† 2:35† — —
50212; 101433 76 23:34 — — — — — — —
3840; 25823 72 — 23:53 23:53 — — — — —
3840; 26271 — 0:00 0:15 — — — — 0:05 —
3840; 26269 — 0:05 — — — — — — —
3840; 26335 75 — 0:45 — — — — — —
4376; 28414 76 — — — 1:47† — 3:17† 0:43 17:44
4376; 101382 76 0:43 2:43 23:00 1:54 2:33 2:13 — 19:50†
8584; 51146 82 1:25 1:50 23:30 1:44 1:50 1:54 — —
8584; 51321 74 0:26 2:13 0:15 1:30 1:30 1:24 — —
8584; 51963 78 0:53 1:15 0:23 — — — — —
50048; 100381 77 0:00 1:08 0:15 — — — 1:23 —
50187; 101263 78 1:40 1:38 22:30 1:31† 0:56† 1:04† 01:53 —
50192; 101311 74 1:08 1:30 23:23 2:23 2:26 — — 17:33
AVG 76.1 0:51 01:19 23:47 01:47 01:52 01:54 01:05 18:22
SD 2.59 0.56 0.55 0.72 0.32 0.67 0.85 0.58 1.27
ID, DNA sample identifier; MEQ, Horne-Ostberg Morningness/Eveningness Questionnaire; GSQ, general sleep questionnaire; MSF, midpoint of sleep on work-free 
days; Intrvw, structured interview; Earliest, earliest possible sleep onset and final wake up time without prior sleep deprivation; SL, sleep log; Zeo, wireless home 
sleep recording system; ACT, actigraphy; PSG, polysomnography; DLMO, dim light melatonin onset; Shaded rows, probands; AVG, average; SD, standard deviation; a, 
data obtained during Daylight Saving Time; -, data not collected.
†Data obtained during Daylight Saving Time.
Table 2.  Self-reported markers of circadian rhythms, excessive daytime sleepiness, and depressive affect in young-onset ASP and conventional 
chronotype family members
Parameter
Conventional ASP
Cohen’s dn M ± SD n M ± SD
MEQ 14 57.21 ± 8.71 17 ***76.1 ± 3.88 2.80
GSQ MSF 11 03:05 ± 1.01 15 ***0:51 ± 0.74 2.87
GSQ MSW 11 02:27 ± 0.90 16 ***0:37 ± 0.55 2.55
Intrvw MSF 14 03:06 ± 1.01 16 ***01:19 ± 0.76 2.09
Intrvw MSW 14 02:36 ± 0.82 15 ***01:10 ± 0.66 1.69
Earliest MSF 11 02:04 ± 0.78 13 ***23:47 ± 0.62 3.65
Speed SO 11 43.27 ± 21.18 14 44.57 ± 16.42 0.07
Speed WU 11 55.27 ± 23.55 14 *76.29 ± 19.11 0.98
ESS 11 11.36 ± 5.01 15 9.80 ± 6.36 0.27
BDI-II 13 6.31 ± 5.98 19 5.63 ± 6.99 0.10
ASP, advanced sleep phase; n, subsample size; M, mean; SD, standard deviation; MEQ, Horne-Ostberg Morningness/Eveningness Questionnaire; GSQ, general sleep 
questionnaire; MSF, midpoint of sleep on work-free days; MSW, midpoint of sleep on workdays; Intrvw, structured interview; Earliest, earliest possible sleep onset 
and final wake up time without prior sleep deprivation; Speed SO, speed of evening sleep onset (visual analog scale from 0-100); Speed WU, speed of morning wake 
up (visual analog scale from 0-100); ESS, Epworth Sleepiness Scale; BDI-II, Beck Depression Inventory-II. 
Student’s two-tailed unpaired t-test *p < .05,  ***p < .001.
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minutes for their conventional chronotype family members 
(Table 2). Latency of final sleep offset (speed of morning wake 
up) was determined using a visual analog scale we developed 
that ranges from 0 to 100: “On awakening most mornings, how 
long does it take you to become fully alert and active?” (0 = sev-
eral hours; 100  =  seconds; Supplementary Figure 2). Our find-
ings suggest that ASP individuals feel alert more quickly in the 
morning, i.e. have less sleep inertia, compared to their conven-
tional chronotype family members (Table 2). The tendency for 
morning types to be more subjectively alert upon awakening 
may be explained, in part, by core body temperature rhythms. 
Previous research suggests that morning types sleep at a later 
portion of their temperature rhythm compared to conventional 
and evening chronotypes [24].
No significant differences were observed in Beck Depression 
Inventory scores between ASP participants and their family 
members with conventional chronotypes (Table 2). This sup-
ports that early morning awakenings observed in ASP and FASP 
probands are not the result of comorbid depression. No signifi-
cant differences were observed between ASP participants and 
their conventional chronotype family members in self-reported 
daytime sleepiness (Table 2). Elevated ESS scores may be ex-
pected for the eight ASP probands who each presented with 
clinical symptoms of EDS related to OSA (n  =  7) or idiopathic 
hypersomnia (n = 1). However, ESS scores from these eight ASP 
probands were combined with ESS scores from seven FASP 
family members (total n  =  15), which may account for these 
nonsignificant results. Sleep quality and quantity are typic-
ally reported as normal for age when ASWPD patients without 
comorbidities allow themselves to fall asleep and awaken 
without regard to social constraints [2].
Our method of screening for FASP began with habitual sleep 
time and thus does not account for individuals who may be ad-
vanced but can easily overcome their circadian clock and sleep 
at a more conventional time. In addition, our criteria rely on 
mid-sleep time on free days and responses to the MEQ, which 
may have excluded some individuals who appear advanced by 
other measures. Although this may lead to an underestimate 
of ASP, our rigorous screening method has proven effective in 
identifying FASP. These strict criteria avoid false positives and 
increase the yield for genetic screening in families with a dom-
inant pattern of inheritance. This method has led to successful 
identification of multiple clock genes that co-segregate in the 
family and are then recapitulated in mouse models [1, 13, 15, 
17, 18]. Therefore, this screening method can translate simple 
questions about sleep timing on an entry sleep clinic question-
naire into identification of families with an autosomal dom-
inant sleep trait and lead to identification of genes controlling 
our circadian clock.
Our ASWPD prevalence estimate of 0.04% includes only those 
individuals presenting with ASP prior to age 30 years. This esti-
mate does not account for individuals with ASP of aging, whose 
schedule advance with aging prompts complaint. Therefore, the 
present estimate likely underestimates the true prevalence of 
ASWPD, even within a sleep clinic population. Figure 1 illus-
trates the relationship between ASP, FASP, ASWPD, and ASP of 
aging. FASP represents the majority of young-onset ASP, and 
a small portion of this group will complain of their advanced 
phase, thus falling into ASWPD. However, some with ASWPD 
may have ASP only due to aging or other unidentified causes. 
Although it is known that chronotype advances with age, the 
formal definition and prevalence of ASP of aging is not defined 
Figure 4. AHI severity does not predict MEQ-determined chronotype. N = 3188. Females, 1491 (mean age = 57.7); males: 1697 (mean age: 59.4). Mean MEQ scores = 62.08 ± 
9.71. Mean AHI scores = 14.08 ± 17.78. Trend line reveals no significant relationship between AHI and MEQ (β = 0.08, SE β = 0.13, p = 0.52, R2 = 1.0 e−5).
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[12]. Therefore, the relative size of the circles in Figure 1 does not 
reflect the relative prevalence of ASP versus ASP of aging, as the 
prevalence of ASP of aging is not known.
The young-onset ASP and FASP prevalence estimates re-
ported here were based on a clinical population presenting to 
an academic medical center. We have also calculated the preva-
lence from the population presenting only for OSA, resulting 
in an ASP prevalence of 0.40% (7/1748) and FASP prevalence of 
0.23% (4/1748). This limited sample was used because we can 
assess whether this sample selects for chronotype and thus can 
consider whether the estimate may have a potential for gen-
eralizability. We conducted a linear regression analysis of MEQ 
and AHI scores from 1324 participants using the Wisconsin 
Sleep Cohort database (Figure 4). Results of this analysis found 
no significant predictive relationship between these variables, 
indicating that using a sleep clinic population presenting for 
symptoms of OSA does not appear to bias the chronotype of 
the sample. Whether our ASP and FASP prevalence estimates 
can be further generalized to the population merits additional 
investigation. In addition, as our team published research on 
FASP beginning in 1999, it is possible this altered the patient 
group seeking care in the clinic, making this clinic estimate less 
representative of other sleep clinics. This is not a population-
based sample.
We aim to raise awareness about ASP and FASP with the 
hope this prompts routine screening, enhancing clinical care for 
those affected. It is notable that many with ASP and FASP are 
not troubled by this sleep pattern. Increased awareness will im-
prove screening for these phenotypes and enrollment in related 
research. Taken together, our findings suggest that ASP and 
FASP subjects routinely present to sleep centers with primary 
complaints that do not appear directly related to sleep–wake 
schedule advance. Our ASP and FASP prevalence estimates are 
higher than one would predict based on the prevailing under-
standing of ASP from ASWPD. Our data support that ASWPD is 
very rare at one out of every 2500. Milder versions or those who 
develop ASP of aging are not accounted for in the dataset.
In our clinical experience, a six-bed sleep clinic running 
five nights per week may see 1500 patients and perform 450 
new diagnostic PSGs annually. Our FASP prevalence estimate 
of 0.21% would predict approximately one incidental FASP 
PSG recording per six-bed sleep center per year. The 2016–2017 
American Academy of Sleep Medicine (AASM) Membership 
Directory (www.aasmnet.org) lists 1512 AASM-accredited sleep 
centers currently operating within the United States. Therefore, 
approximately 1000 diagnostic PSG recordings may be per-
formed on potential OSA patients who also have FASP in the 
United States annually. This number is likely conservative, as 1 
615 135 PSG recordings were estimated to have been performed 
in the United States in the year 2001 [35]. Assuming only 50% 
of these recordings were performed for new patient OSA evalu-
ations, our FASP prevalence in an OSA population estimate of 
0.23% predicts 1857 PSG recordings were performed on potential 
OSA patients with FASP in 2001 alone. To the best of our know-
ledge, only 11 FASP families have been reported to date [1, 15–18, 
36, 37], suggesting that there is potential to identify far more 
FASP individuals during routine clinic evaluation.
Individuals with ASP often complain of a longstanding pat-
tern of evening sleepiness and early morning awakening with 
trouble returning to sleep. They may have shorter sleep hours 
if attempting to stay up for social, work, or family obligations 
without the ability to awaken later. There is a growing body 
of literature linking fewer hours of sleep to multiple negative 
health outcomes, including increased mortality, diabetes mel-
litus, hypertension, cardiovascular disease, and obesity [38]. It is 
essential for clinicians to appreciate the circadian explanation 
for shorter sleep hours for this patient population to provide ap-
propriate counseling and treatment options.
Therefore, we recommend routine screening for circadian 
phenotypes in all sleep clinics with two questions:
 (1) On a long weekend or vacation with few or no responsibil-
ities or obligations, when would you go to bed?
 (2) On a long weekend or vacation with few or no responsibil-
ities or obligations, when is your final awakening for the 
night?
These simple questions included in new patient packets can 
allow the clinician to screen for both ASP and delayed sleep 
phase, with follow-up questions if atypical timing is noted. 
Asking about long weekend and vacation rhythms is important 
to remove the extrinsic demands of school, work, and family 
and rebound sleep during weekends.
Recognizing that extreme sleep–wake schedule advance is 
not exceedingly rare may assist clinicians in separating the early 
morning awakenings of ASP from the early morning awaken-
ings of insomnia, nocturia, environmental sleep disruptions, 
and major depressive disorder. Identifying FASP subjects will re-
quire clinicians to routinely ask about habitual workday and free 
day sleep–wake schedules and explore familial patterns of ASP if 
extreme sleep–wake schedule advances are described. Our find-
ings further suggest that ASP individuals with onset prior to age 
30 years should be considered likely FASP probands.
Importantly, the clinical identification of young-onset FASP 
individuals and their family members has facilitated the dis-
covery of autosomal dominant circadian clock gene mutations 
in PER2 [13, 14], CKIδ [15, 16], PERIOD3 [17], CRY2 [18], TIM [39], 
and DEC2 [19]. FASP clock gene mutations have been found to 
co-segregate with familial migraine (cK1δ) [15] and depressive 
affect (PER3) [17], and regulatory roles for core clock genes in 
tumor suppression [40], sugar metabolism [41], behavioral ac-
tivation [19], and the age of onset of bipolar disorder [42] have 
been reported. Therefore, functional characterization of newly 
discovered clock gene mutations may lead to improved treat-
ment options for a wide range of sleep and medical disorders in 
the future. Our findings provide an indication and mechanism 
for clinicians to routinely screen for ASP and FASP subjects.
Supplementary material
Supplementary material is available at SLEEP online.
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